TY - JOUR
T1 - Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood
AU - Toperoff, Gidon
AU - Aran, Dvir
AU - Kark, Jeremy D.
AU - Rosenberg, Michael
AU - Dubnikov, Tatyana
AU - Nissan, Batel
AU - Wainstein, Julio
AU - Friedlander, Yechiel
AU - Levy-Lahad, Ephrat
AU - Glaser, Benjamin
AU - Hellman, Asaf
N1 - Funding Information: This work was supported by the United States-Israel Binational Science Foundation (to J.D.K.), the Breast Cancer Research Foundation and The Israeli HPR (to E.L.L.), the Russell Berry Foundation/D Cure (to B.G.), the Israel Cancer Research Fund (to A.H.), the NIH research grant R01HL088884 (to Y.F.) and the Israel Science Foundation (to A.H., to Y.F. and to J.D.K.).
PY - 2012/1
Y1 - 2012/1
N2 - Inter-individual DNA methylation variations were frequently hypothesized to alter individual susceptibility to Type 2 Diabetes Mellitus (T2DM). Sequence-influenced methylations were described in T2DM-associated genomic regions, but evidence for direct, sequence-independent association with disease risk is missing. Here, we explore disease-contributing DNA methylation through a stepwise study design: first, a pool-based, genome-scale screen among 1169 case and control individuals revealed an excess of differentially methylated sites in genomic regions that were previously associated with T2DM through genetic studies. Next, in-depth analyses were performed at selected top-ranking regions. A CpG site in the first intron of the FTO gene showed small (3.35%) but significant (P = 0.000021) hypomethylation of cases relative to controls. The effect was independent of the sequence polymorphism in the region and persists among individuals carrying the sequence-risk alleles. The odds of belonging to the T2DM group increased by 6.1% for every 1% decrease in methylation (OR = 1.061, 95% CI: 1.032-1.090), the odds ratio for decrease of 1 standard deviation of methylation (adjusted to gender) was 1.5856 (95% CI: 1.2824-1.9606) and the sensitivity (area under the curve = 0.638, 95% CI: 0.586-0.690; males = 0.675, females = 0.609) was better than that of the strongest known sequence variant. Furthermore, a prospective study in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to T2DM, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators. The data showed that low methylation level at the analyzed sites is an early marker of T2DM and suggests a novel mechanism by which early-onset, inter-individual methylation variation at isolated non-promoter genomic sites predisposes to T2DM.
AB - Inter-individual DNA methylation variations were frequently hypothesized to alter individual susceptibility to Type 2 Diabetes Mellitus (T2DM). Sequence-influenced methylations were described in T2DM-associated genomic regions, but evidence for direct, sequence-independent association with disease risk is missing. Here, we explore disease-contributing DNA methylation through a stepwise study design: first, a pool-based, genome-scale screen among 1169 case and control individuals revealed an excess of differentially methylated sites in genomic regions that were previously associated with T2DM through genetic studies. Next, in-depth analyses were performed at selected top-ranking regions. A CpG site in the first intron of the FTO gene showed small (3.35%) but significant (P = 0.000021) hypomethylation of cases relative to controls. The effect was independent of the sequence polymorphism in the region and persists among individuals carrying the sequence-risk alleles. The odds of belonging to the T2DM group increased by 6.1% for every 1% decrease in methylation (OR = 1.061, 95% CI: 1.032-1.090), the odds ratio for decrease of 1 standard deviation of methylation (adjusted to gender) was 1.5856 (95% CI: 1.2824-1.9606) and the sensitivity (area under the curve = 0.638, 95% CI: 0.586-0.690; males = 0.675, females = 0.609) was better than that of the strongest known sequence variant. Furthermore, a prospective study in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to T2DM, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators. The data showed that low methylation level at the analyzed sites is an early marker of T2DM and suggests a novel mechanism by which early-onset, inter-individual methylation variation at isolated non-promoter genomic sites predisposes to T2DM.
UR - http://www.scopus.com/inward/record.url?scp=84855400734&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/hmg/ddr472
DO - https://doi.org/10.1093/hmg/ddr472
M3 - مقالة
C2 - 21994764
SN - 0964-6906
VL - 21
SP - 371
EP - 383
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 2
M1 - ddr472
ER -
